Morgan Stanley raised the firm’s price target on Medacta Group (MEDGF) to CHF 146 from CHF 136 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDGF:
- Medacta Group SA Reports Strong 2024 Financial Growth
- Medacta Group SA Achieves Robust Growth in 2024 with Innovative Orthopedic Solutions
- Medacta Group SA: Strong Financial Performance and Growth Potential Justify Buy Rating
- Medacta Group price target raised to CHF 160 from CHF 150 at Berenberg
- Medacta Group price target raised to CHF 136 from CHF 135 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue